Patients with residual disease after neoadjuvant therapy still face a significant risk of recurrence — especially those with node-positive disease.
This clip explores why DESTINY-Breast 05 matters, how T-DXd compares to T-DM1, and why CNS recurrence risk is changing how clinicians think about adjuvant therapy.
Why T-DXd Could Replace T-DM1 in High-Risk Patients
You may also like
Recommended Videos
